The CEO can say what he wants - not controlling for HA just makes it a weaker study. They can do whatever study they want, but they're cutting corners and that will effect the impact of the results.
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-372
-
- There are more pages in this discussion • 178 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.30 |
Change
0.015(1.17%) |
Mkt cap ! $1.467B | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.31 | $1.27 | $1.201M | 934.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 16315 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 36605 | 6 |
View Market Depth
| Last trade - 15.08pm 05/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |